Value
4.3/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 0.2 |
| Fwd P/E | 4.9 |
| PEG | 10.0 |
| Analyst target | 6.0 |
- ▸Forward P/E: 25.6x
- ▸PEG: 0.05
CORT · Why this verdict
Why Corcept Therapeutics Incorporat (CORT) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.9/10
ConfidenceMEDIUM
MacroRISK_OFF
TrendMatrix Research · core thesis
Engine thesis — one sentence
Corcept has reached its take-profit ceiling at $83.09 with a negative risk/reward and 15% downside; two consecutive earnings misses have broken the prior beat streak, and a put/call ratio of 4.44 with 11% short interest signals heavy bearish market positioning — making the current setup unfavorable despite strong momentum readings.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The stock has reached the take-profit level at $83.09 with a negative asymmetry ratio — approximately 15% downside versus no remaining upside — and the risk/reward does not favor holding or adding to a position at these levels. Price targets | Over the next 12 months, either the share price retreats toward a more favorable entry point, or analyst price targets are raised materially above the current ceiling to restore positive asymmetry; neither outcome has materialized yet. | Tripped↑Improving |
| CounterIf earnings estimates continue trending upward as suggested by analyst activity, targets may be revised higher, shifting the risk/reward back to favorable and making the current price a reasonable entry rather than a ceiling. | ||
After two beats in the two older quarters, the company has missed earnings estimates in each of the two most recent reporting periods — with the most recent miss of -111% and the prior miss of -39% — indicating a meaningful deterioration in near-term earnings execution. Earnings | Earnings estimates should be revised lower to reflect the recent miss cadence; if the next quarter beats estimates, the miss streak would be broken and the short-term execution concern would ease. | ↑Improving |
| CounterTwo beats in the prior periods demonstrate the business has the capacity to outperform; the recent misses may reflect one-time charges or timing items rather than a structural deterioration in profitability. | ||
A put/call ratio of 4.44 and short interest of 11% of float indicate that the market is positioned heavily against the stock; this level of bearish positioning often reflects genuine concerns about the business outlook, and the concentration of negative bets can amplify downside if sentiment deteriorates further. Risk breakdown | Put/call ratio should compress below 1.5 and short interest should fall below 8% of float as bearish catalysts clear; persistent elevation of both metrics would confirm that market participants see unresolved risks. | ↓Deteriorating |
| CounterExtreme bearish positioning can set up a rapid recovery if any positive catalyst emerges; a constructive earnings result or product development milestone could rapidly unwind the short position and drive the stock sharply higher. | ||
The RSI has reached 91 while the moving average slope is flat to negative — a combination flagged as late-cycle distribution risk — suggesting the recent price advance may be running ahead of fundamentals and could be approaching exhaustion. Momentum breakdown | RSI should retreat below 70 within the next 1-2 months without the stock breaking materially lower; if RSI normalizes through sideways price action rather than a sharp correction, the overextension will have resolved constructively. | ↑Improving |
| CounterVolume accumulation (rising OBV) and MACD improvement indicate buying support beneath the overbought surface reading; elevated RSI in strong momentum regimes can persist for extended periods before reverting. | ||
Three HIGH-severity concentration risks are flagged — including a single counterparty (Curant) and a single product line — making the revenue base highly exposed to failure at any single node, with limited diversification to absorb a disruption. Bear case | Any single-counterparty revenue contribution should begin declining as a share of total revenue within 12 months; if Curant remains responsible for more than 40% of revenue after two additional quarters, the concentration risk has not meaningfully diminished. | ↓Deteriorating |
| CounterDeep counterparty relationships in specialty pharma can reflect contractual lock-in and pricing power rather than fragility; a single dominant partner generating reliable, recurring revenue may be more durable than a diversified but lower-quality revenue mix. | ||
The stock has reached the take-profit level at $83.09 with a negative asymmetry ratio — approximately 15% downside versus no remaining upside — and the risk/reward does not favor holding or adding to a position at these levels.
Tripped↑ImprovingPrice targets
- Expectation
- Over the next 12 months, either the share price retreats toward a more favorable entry point, or analyst price targets are raised materially above the current ceiling to restore positive asymmetry; neither outcome has materialized yet.
CounterIf earnings estimates continue trending upward as suggested by analyst activity, targets may be revised higher, shifting the risk/reward back to favorable and making the current price a reasonable entry rather than a ceiling.
After two beats in the two older quarters, the company has missed earnings estimates in each of the two most recent reporting periods — with the most recent miss of -111% and the prior miss of -39% — indicating a meaningful deterioration in near-term earnings execution.
↑ImprovingEarnings
- Expectation
- Earnings estimates should be revised lower to reflect the recent miss cadence; if the next quarter beats estimates, the miss streak would be broken and the short-term execution concern would ease.
CounterTwo beats in the prior periods demonstrate the business has the capacity to outperform; the recent misses may reflect one-time charges or timing items rather than a structural deterioration in profitability.
A put/call ratio of 4.44 and short interest of 11% of float indicate that the market is positioned heavily against the stock; this level of bearish positioning often reflects genuine concerns about the business outlook, and the concentration of negative bets can amplify downside if sentiment deteriorates further.
↓DeterioratingRisk breakdown
- Expectation
- Put/call ratio should compress below 1.5 and short interest should fall below 8% of float as bearish catalysts clear; persistent elevation of both metrics would confirm that market participants see unresolved risks.
CounterExtreme bearish positioning can set up a rapid recovery if any positive catalyst emerges; a constructive earnings result or product development milestone could rapidly unwind the short position and drive the stock sharply higher.
The RSI has reached 91 while the moving average slope is flat to negative — a combination flagged as late-cycle distribution risk — suggesting the recent price advance may be running ahead of fundamentals and could be approaching exhaustion.
↑ImprovingMomentum breakdown
- Expectation
- RSI should retreat below 70 within the next 1-2 months without the stock breaking materially lower; if RSI normalizes through sideways price action rather than a sharp correction, the overextension will have resolved constructively.
CounterVolume accumulation (rising OBV) and MACD improvement indicate buying support beneath the overbought surface reading; elevated RSI in strong momentum regimes can persist for extended periods before reverting.
Three HIGH-severity concentration risks are flagged — including a single counterparty (Curant) and a single product line — making the revenue base highly exposed to failure at any single node, with limited diversification to absorb a disruption.
↓DeterioratingBear case
- Expectation
- Any single-counterparty revenue contribution should begin declining as a share of total revenue within 12 months; if Curant remains responsible for more than 40% of revenue after two additional quarters, the concentration risk has not meaningfully diminished.
CounterDeep counterparty relationships in specialty pharma can reflect contractual lock-in and pricing power rather than fragility; a single dominant partner generating reliable, recurring revenue may be more durable than a diversified but lower-quality revenue mix.
Per-dimension breakdown
Quality
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 2.7 |
| ROA | 0.3 |
| Gross margin | 10.0 |
| Op margin | 6.4 |
| Net margin | 3.3 |
| Current ratio | 9.6 |
| FCF quality | 9.7 |
| Moat | 7.9 |
| Rule of 40 | 7.1 |
| Piotroski F | 10.0 |
- ▸Excellent cash conversion: 140% FCF/NI
- ▸Wide economic moat
- ▸Rule of 40: 41 (pass)
- ▸Strong Piotroski F-Score: 9/9
Growth
8.4/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
| EPS growth | 6.8 |
- ▸Strong growth: 32% YoY
Momentum
5.1/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 7.7 |
| MACD | 0.0 |
| OBV | 10.0 |
| MA position | 6.0 |
| Volume | 1.7 |
- ▸Uptrend pullback (RSI 38) - buy opportunity
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 6.5 |
| Price target | 8.3 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (5.0) — signal dampened
- ▸Analyst upside: 26%
Insider
3.4/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 5.3 |
- ▸Notable insider selling — $35,455,983 (0.291% of mkt cap)
Peer rank
5.6/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 1.9 |
| quality rank | 7.0 |
| growth rank | 6.2 |
- ▸Superior ROE vs peers
Technical
7.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 7.5 |
| support resistance | 8.4 |
| 52w position | 7.7 |
| gap | 6.0 |
Risk (lower is worse)
4.5/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 4.2 |
| days to cover | 2.6 |
| volatility | 2.6 |
| put call | 0.0 |
| implied vol | 2.4 |
| beta | 10.0 |
| debt equity | 9.9 |
- ▸Elevated put/call: 2.96
- ▸High IV: 65%
- ▸Concentration risks: 3 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Maintain position. Not compelling to add more. | News modifier -1 (HOLD_IF_HOLDING → SELL_IF_HOLDING).
Engine technical detail
verdict_path:
L4:PATH_F_HOLD|L3:NEWS_MOD=-1Passed (6)
- MOMENTUM:5.1>=4.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:61d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:1.2<1.5@spot
Warning (2)
- MOMENTUM:5.1<5.5 (soft — BUY_NOW allowed but watch)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
1.25
Upside
+9.9%
Downside
7.9%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: MOMENTUM:5.1>=4.5. Top dim: Growth at 8.4; weakest: Insider at 3.4. No conviction either direction.
The strongest dimensions are Growth at 8.4, Technical at 7.4, and Quality at 6.7; the weakest are Insider at 3.4, Value at 4.3, and Risk (lower is worse) at 4.5. The V9 engine flagged 1 failed gate with 2 warnings, producing an asymmetric reward-to-risk of 1.25 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Price At Take Profit Negative AsymmetryTripped
Trip ifConsensus analyst price target rises above $95.00, providing more than 14% upside from current levels and restoring a positive risk/reward.
- P2Two Consecutive Earnings Misses
Trip ifEPS surprise rises above 0% for 2 consecutive quarters, re-establishing the prior beat pattern.
- P3Elevated Put Call High Short Interest
Trip ifPut/call ratio falls below 1.5 AND short interest falls below 8% of float, indicating bearish positioning has substantially unwound.
- P4Overbought Rsi Late Cycle Distribution
Trip ifShare price remains above $78.00 while RSI retreats below 70 within 3 months, confirming the overbought advance resolved without a meaningful correction.
- P5Three High Concentration Risks
Trip ifSingle counterparty revenue concentration falls below 40% of total revenue for 2 consecutive quarters.